## AVAILABILITY OF LAM TESTING IN COUNTRIES WITH HIGH BURDENS OF TB AND HIV

## February 2020

YES

PENDING\*

According to data available at the time of publication, 13 countries with high burdens of TB and HIV have incorporated LAM testing into their national guidelines for the diagnosis of TB in people living with HIV. However, just seven countries—the Democratic Republic of the Congo, Kenya, Malawi, Myanmar, South Africa, Uganda, and Zimbabwe—have translated policy into practice by rolling out the use of LAM within their national programs. The table below represents the state of LAM testing availability in high-TB-and-HIV-burden countries and indicates where targeted advocacy interventions can help improve access to this life-saving test for TB among people living with HIV.

PLANNING

NO

NO DATA

High-TB/HIV-Burden Countries <sup>1</sup>	LAM in National TB and/or HIV Guidelines <sup>2,3</sup>	LAM Registered With National Regulatory Authority <sup>4</sup>	LAM Procured by National Program in 2018 <sup>5</sup>	LAM in Routine Use in National Program 6,7,8,9,10,11
Angola	•			
Botswana			•	
Brazil	•			
Cameroon	•	•		
Central African Republic				
Chad				
China		•	•	•
Congo	•			
Democratic Republic of the Congo	•			
Eswatini	•	•	•	•
Ethiopia	•	•	•	
Ghana	•	•	•	•
Guinea-Bissau	•		•	•
India	•	•	•	•
Indonesia	•	•	•	
Kenya	•	•	•	•
Lesotho	•	•	•	
Liberia	•	•	•	•
Malawi	•	•	•	
Mozambique	•		•	
Myanmar		•	•	
Namibia	•			
Nigeria		•	•	•
Papua New Guinea	•	•	•	
South Africa			•	
Tanzania	•	•	•	•
Thailand	•	•	•	•
Uganda	•	•	•	•
Zambia				•
Zimbabwe				

<sup>\*</sup> Countries that procured LAM with registrations pending utilized temporary import permits or waivers.

## **REFERENCES**

- World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. https://www.who.int/tb/publications/global\_report/en/.
- 2. Ibid.
- Singhroy DN, MacLean E, Kohli M, et al. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers [version 1; peer review; awaiting peer review]. Gates Open Res [Internet]. 2020 Feb 13 (cited 2020 Feb 13);4:24. Available from: https://doi.org/10.12688/ gatesopenres.13112.1.
- O'Shea, Rachel (Abbott Rapid Diagnostics, Galway, Ireland). Personal communication with: David Branigan (Treatment Action Group, New York, USA). 2020 January 27.
- Ibid
- Singhroy DN, MacLean E, Kohli M, et al. Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers [version 1; peer review: awaiting peer review].
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Eswatini Country Operational Plan 2019 (COP19) Strategic Direction Summary. U.S. Department of State: 2019 April 5. Available from: https://www.state.gov/wp-content/uploads/2019/09/Eswatini\_COP19-Strategic-Directional-Summary\_public.pdf.

- 8. U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Kenya Country Operational Plan 2019 (COP19) Strategic Direction Summary. U.S. Department of State: 2019 July 2. Available from: https://www.state.gov/where-we-work-pepfar/.
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Lesotho Country Operational Plan 2019 (COP19) Strategic Direction Summary. U.S. Department of State: 2019 April 5. Available from: https://www.state.gov/wp-content/uploads/2019/09/Lesotho\_COP19-Strategic-Directional-Summary\_public.pdf.
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Namibia Country Operational Plan 2019 (COP19) Strategic Direction Summary. U.S. Department of State: 2019 April 5. Available from: https://www.state.gov/wp-content/uploads/2019/09/Namibia\_COP19-Strategic-Directional-Summary\_public.pdf.
- U.S. President's Emergency Plan for AIDS Relief (PEPFAR). South Africa Country Operational Plan 2019 (COP19) Strategic Direction Summary. U.S. Department of State: 2019 August 22. Available from: https://www.state.gov/wp-content/uploads/2019/09/South-Africa\_ COP19-Strategic-Directional-Summary\_public.pdf.



www.treatmentactiongroup.org
90 Broad Street, Suite 2503 New York, NY 10004
Tel 212.253.7922, Fax 212.253.7923
tag@treatmentactiongroup.org